OncoGenex Announces Completion Of Patient Enrollment In Custirsen Phase 3 "SYNERGY" Study

  OncoGenex Announces Completion Of Patient Enrollment In Custirsen Phase 3
                               "SYNERGY" Study

Primary Registration Phase 3 Study for Custirsen in Advanced Prostate Cancer
Now Fully Enrolled

PR Newswire

BOTHELL, Wash. and VANCOUVER, British Columbia, Nov. 6, 2012

BOTHELL, Wash. and VANCOUVER, British Columbia, Nov. 6, 2012 /PRNewswire/
--OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today the
completion of patient enrollment in the primary registration Phase 3 study,
known as SYNERGY, evaluating custirsen in patients with advanced prostate
cancer.

The SYNERGY study is designed to evaluate a survival benefit for custirsen,
when added to first-line chemotherapy, in men with metastatic
castrate-resistant prostate cancer (mCRPC). The SYNERGY study is the first of
two, ongoing, pivotal Phase 3 studies evaluating a potential survival benefit
for custirsen treatment in prostate cancer.

Over 1000 men have been enrolled to the SYNERGY study, at 142 sites primarily
in North America and Europe. The survival primary endpoint data are
event-driven and results are expected by the end of 2013.

"Completing enrollment of SYNERGY is an exciting and important milestone for
the custirsen development program and for our company," said Scott Cormack,
President and CEO of OncoGenex Pharmaceuticals. "We are one step closer to our
goal of truly understanding the clinical benefit of custirsen in a large,
randomized Phase 3 study, and to bringing forward a new treatment that could
potentially extend the lives of men with prostate cancer."

The SYNERGY trial was initiated based on results of the OncoGenex Phase 2
trial in patients with metastatic CRPC receiving custirsen in combination with
first-line docetaxel chemotherapy. These patients experienced a 6.9 month
improvement in overall survival in comparison with those patients who received
docetaxel alone.

Custirsen has received Fast Track designation from the FDA for the treatment
of progressive metastatic prostate cancer in combination with docetaxel. The
FDA has also agreed on the design of the SYNERGY trial through the special
protocol assessment (SPA) process.

ABOUT CUSTIRSEN
Custirsen is the only compound currently in development designed to inhibit
the production of clusterin, a protein commonly over-produced in cancer cells,
and one cause of treatment resistance. As part of Phase 1 and Phase 2 clinical
trials, custirsen was administered to 294 patients with various types of
cancer. Some of the patients experienced a variety of adverse events, the
majority of which were associated with other treatments in the protocol and
the disease. The majority of adverse events were mild and the most common
adverse events associated with custirsen consisted of flu-like symptoms. The
most common serious adverse events (SAE) associated with custirsen were
febrile neutropenia, fever, pleural effusion, and dyspnea. Each SAE event was
observed in approximately 2%-4% of patients.

ABOUT ONCOGENEX
OncoGenex is a biopharmaceutical company committed to the development and
commercialization of new therapies that address treatment resistance in cancer
patients. OncoGenex has a diverse oncology pipeline, with each product
candidate having a distinct mechanism of action and representing a unique
opportunity for cancer drug development.OncoGenexandTeva Pharmaceutical
Industries Ltd.(NYSE:TEVA) have entered a global collaboration and license
agreement to develop and commercialize OncoGenex' lead drug candidate,
custirsen. Custirsen is currently in Phase 3 clinical development as a
treatment in men with metastatic castrate-resistant prostate cancer and in
patients with advanced, unresectable non-small cell lung cancer. OGX-427 is in
Phase 2 clinical development and OGX-225 is currently in pre-clinical
development. More information is available at www.OncoGenex.com.

OncoGenex' Forward Looking Statements
This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995, including, but not limited to, statements concerning our anticipated
product development activities, such as expected clinical trial completion and
statements regarding the potential benefits and potential development of our
product candidates. All statements other than statements of historical fact
are statements that could be deemed forward-looking statements. These
statements are based on management's current expectations and beliefs and are
subject to a number of risks, uncertainties and assumptions that could cause
actual results to differ materially from those described in the
forward-looking statements. Such forward-looking statements are subject to
risks and uncertainties, including, among others, the risk that final trial
results will not demonstrate the same or any potential benefit as observed in
preliminary trial results, the risk that subsequent studies may not confirm
earlier trial results, the risk of delays in our expected clinical trials, the
risk that new developments in the rapidly evolving cancer therapy landscape
require changes in our clinical trial plans or limit the potential benefits of
our product, the risk that our cash resources are insufficient to fund our
planned activities for the time period expected and the other factors
described in our risk factors set forth in our filings with the Securities and
Exchange Commission from time to time, including the Company's Annual Report
on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no
obligation to update the forward-looking statements contained herein or to
reflect events or circumstances occurring after the date hereof, other than as
may be required by applicable law.

SOURCE OncoGenex Pharmaceuticals, Inc.

Website: http://www.OncoGenex.com
Contact: Media: Jaime Welch, +1-604-630-5403, jwelch@oncogenex.com; Investor
Relations: Susan Specht, +1-425-686-1535, sspecht@oncogenex.com